Re:Transition Agreement Dear John: This letter sets forth the substance of the Transition Agreement (the “Transition Agreement” or “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you.
February 14, 2023
Modified February 21, 2023
Xxxx Xxxxxxx, Ph.D.
00000 Xxx Xxxx
Gaithersburg MD 20878
E-mail: xxxxxxxx@xxxxxxxxxxxxx.xxx
Dear Xxxx:
This letter sets forth the substance of the Transition Agreement (the “Transition Agreement” or “Agreement”) which GlycoMimetics, Inc. (the “Company”) is offering to you.
If you are currently participating in the Company’s group health insurance plans (e.g., medical, dental, vision), your participation as an employee will end on the Separation Date. Thereafter, to the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense, subject to Section 2(b). Later, you may be able to
convert to an individual policy through the provider of the Company’s health insurance, if you wish.
Your participation in Employer-Sponsored Group Life Insurance and Short and Long Term Disability Insurance will also cease as of the Separation Date.
• | has violated its personnel policies, handbooks, contracts of employment, or covenants of good faith and fair dealing; |
• | has discriminated against you on the basis of age, race, color, sex (including sexual harassment), national origin, ancestry, disability, religion, sexual orientation, marital status, parental status, source of income, entitlement to benefits, any union activities or other protected category in violation of any local, state or federal law, constitution, ordinance, or regulation, including but not limited to: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; 42 U.S.C. § 1981, as amended; the Equal Pay Act; the Americans With Disabilities Act; the Genetic Information Nondiscrimination Act; the Family and Medical Leave Act; |
the Fair Employment Practice Act of Maryland, Md. Code Xxx., State Government, tit. 20; the Employee Retirement Income Security Act; the Employee Polygraph Protection Act; the Worker Adjustment and Retraining Notification Act; the Older Workers Benefit Protection Act; the anti-retaliation provisions of the Xxxxxxxx-Xxxxx Act, or any other federal or state law regarding whistleblower retaliation; the Xxxxx Xxxxxxxxx Fair Pay Act; the Uniformed Services Employment and Reemployment Rights Act; the Fair Credit Reporting Act; and the National Labor Relations Act; |
• | has violated any statute, public policy or common law (including but not limited to Claims for retaliatory discharge; negligent hiring, retention or supervision; defamation; intentional or negligent infliction of emotional distress and/or mental anguish; intentional interference with contract; negligence; detrimental reliance; loss of consortium to you or any member of your family and/or promissory estoppel). |
Notwithstanding the foregoing, other than events expressly contemplated by this Agreement you do not waive or release rights or Claims that may arise from events that occur after the date this waiver is executed and you are not releasing any right of indemnification you may have for any liabilities arising from your actions within the course and scope of your employment with the Company or within the course and scope of your role as an employee of the Company. Also excluded from this Agreement are any Claims which cannot be waived by law, including, without limitation, any rights you may have under applicable workers’ compensation laws and your right, if applicable, to file or participate in an investigative proceeding of any federal, state or local governmental agency. Nothing in this Agreement shall prevent you from filing, cooperating with, or participating in any proceeding or investigation before the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal government agency, or similar state or local agency (“Government Agencies”), or exercising any rights pursuant to Section 7 of the National Labor Relations Act. You further understand this Agreement does not limit your ability to voluntarily communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, you are otherwise waiving, to the fullest extent permitted by law, any and all rights you may have to individual relief based on any Claims that you have released and any rights you have waived by signing this Agreement. If any Claim is not subject to release, to the extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a Claim in which any of the Company Parties is a party. This Agreement does not abrogate your existing rights under any Company benefit plan or any plan or agreement related to equity ownership in the Company; however, it does waive, release and forever discharge Claims existing as of the date you execute this Agreement pursuant to any such plan or agreement.
If this Agreement is acceptable to you, please sign and date below by no later than 11:59 a.m. Eastern Time on February 21, 2023, and then send me the fully signed Agreement.
I thank you for your efforts to date on behalf of the Company and thank you in advance for your cooperation in successfully completing the Transition Period. I also wish you good luck in your future endeavors.
[Signatures to follow on next page]
Sincerely,
By: /s/ Xxxxxx Xxxxxxxxx
Name: Xxxxxx Xxxxxxxxx
Title: President and Chief Executive Officer
Agreed to and Accepted:
/s/ Xxxx Xxxxxxx
Xxxx Xxxxxxx, Ph.D.
Exhibit A – Updated Release of Claims
Exhibit B – Consulting Agreement
Exhibit C – Equity
Exhibit D – Compliance Agreement
Exhibit A
Updated Release of Claims
GlycoMimetics, Inc. (the “Company”) and Xxxx Xxxxxxx, Ph.D. (the “Employee”) entered into a Transition Agreement dated February 21, 2023 (“Agreement”). Capitalized terms not defined herein shall have the meaning set forth in the Agreement. The parties to that Agreement hereby further agree as follows:
1.A blank copy of this Updated Release of Claims (“Updated Release”) was attached to the Agreement as Exhibit A, which Employee received on February 14, 2023.
0.Xx consideration of the provision to the Employee of the Transition Benefits (cash severance, COBRA premiums and payments and the consulting opportunity) described in and as defined in Section 2 of the Agreement for which the Employee becomes eligible only if the Employee signs this Updated Release and does not revoke the Employee’s acceptance, the Employee, on behalf of the Employee and, to the extent permitted by law, on behalf of the Employee’s spouse, heirs, executors, administrators, assigns, insurers, attorneys and other persons or entities, acting or purporting to act on the Employee’s behalf (collectively, the “Employee Parties”), hereby generally and completely releases, acquits and forever discharges the Company, its parents and subsidiaries, and its and their officers, directors, managers, partners, agents, representatives, employees, attorneys, shareholders, predecessors, successors, assigns, insurers and affiliates (the “Company Parties”) of and from any and all claims, liabilities, demands, contentions, actions, causes of action, suits, costs, expenses, attorneys’ fees, damages, indemnities, debts, judgments, levies, executions and obligations of every kind and nature, in law, equity, or otherwise, both known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, events, acts or conduct at any time prior to and including the execution date of this Updated Release, including but not limited to: all such claims and demands directly or indirectly arising out of or in any way connected with the Employee’s employment with the Company or the termination of that employment; claims under the Employment Agreement; claims or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of compensation; claims pursuant to any federal, state or local law, statute, or cause of action; tort law; or contract law (individually a “Claim” and collectively “Claims”). The Claims the Employee is releasing and waiving in this Updated Release include, but are not limited to, any and all Claims that any of the Company Parties:
A-1
Notwithstanding the foregoing, other than events expressly contemplated by this Updated Release, the Employee does not waive or release rights or Claims that may arise from events that occur after the date this waiver is executed, and the Employee is not releasing any right of indemnification the Employee may have for any liabilities arising from the Employee’s actions within the course and scope of the Employee’s employment with the Company or within the course and scope of the Employee’s role as an employee of the Company. In addition, the Employee is not waiving any rights the Employee may have to unemployment compensation. Also excluded from this Updated Release are any Claims which cannot be waived by law, including, without limitation, any rights the Employee may have under applicable workers’ compensation laws and the Employee’s right, if applicable, to file or participate in an investigative proceeding of any federal, state or local governmental agency. Nothing in this Updated Release shall prevent the Employee from filing, cooperating with, or participating in any proceeding or investigation before the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal government agency, or similar state or local agency (“Government Agencies”), or exercising any rights pursuant to Section 7 of the National Labor Relations Act. The Employee further understands this Updated Release does not limit the Employee’s ability to voluntarily communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Updated Release does not limit the Employee’s right to receive an award for information provided to the Securities and Exchange Commission, the Employee understands and agrees that, the Employee is otherwise waiving, to the fullest extent permitted by law, any and all rights the Employee may have to individual relief based on any Claims that the Employee has released and any rights the Employee has waived by signing this Updated Release. If any Claim is not subject to release, to the extent permitted by law, the Employee waives any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a Claim in which any of the Company Parties is a party. This Updated Release does not abrogate the Employee’s existing rights under any Company benefit plan or any plan or agreement related to equity ownership in the Company;
A-2
however, it does waive, release and forever discharge Claims existing as of the date the Employee executes this Updated Release pursuant to any such plan or agreement.
3.The Employee acknowledges that the Employee is knowingly and voluntarily waiving and releasing any and all rights the Employee may have under the ADEA, as amended. The Employee also acknowledges and agrees that (i) the consideration given to the Employee in exchange for the waiver and release in this Updated Release is in addition to anything of value to which the Employee was already entitled, and (ii) that the Employee has been paid for all time worked, has received all the leave, leaves of absence and leave benefits and protections for which the Employee is eligible, and has not suffered any on-the-job injury for which the Employee has not already filed a Claim. The Employee affirms that all of the decisions of the Company Parties regarding the Employee’s pay and benefits through the date of the Employee’s execution of this Updated Release were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law. The Employee affirms that the Employee has not filed or caused to be filed, and is not presently a party to, a Claim against any of the Company Parties. The Employee further affirms that the Employee has no known workplace injuries or occupational diseases. The Employee acknowledges and affirms that the Employee has not been retaliated against for reporting any allegation of corporate fraud or other wrongdoing by any of the Company Parties, or for exercising any rights protected by law, including any rights protected by the Fair Labor Standards Act, the Family Medical Leave Act or any related statute or local leave or disability accommodation laws, or any applicable state workers’ compensation law. The Employee further acknowledges and affirms that the Employee has been advised by this writing that: (a) the Employee’s waiver and release do not apply to any rights or Claims that may arise after the execution date of this Updated Release; (b) the Employee has been advised hereby that the Employee has the right to consult with an attorney prior to executing this Updated Release; (c) the Employee has been given at least twenty-one (21) days from receipt to consider this Updated Release; (d) the Employee has seven (7) days following the Employee’s execution of this Updated Release to revoke this Updated Release; and (e) this Updated Release shall not be effective until the date upon which the revocation period has expired unexercised, which shall be the eighth day after this Updated Release is executed by the Employee.
4.The parties agree that this Updated Release is a part of the Agreement.
[signatures to follow on next page]
A-3
GlycoMimetics, Inc.
By: ____________________________________
Name: Xxxxxx Xxxxxxxxx
Title: President and Chief Executive Officer
Xxxx Xxxxxxx, Ph.D.
A-4
Exhibit B
Consulting Agreement
This Consulting Agreement (the “Agreement”) by and between GlycoMimetics, Inc. (“Client”) and Xxxx Xxxxxxx, Ph.D., an individual (“Consultant”) is effective as of March 31, 2023 (the “Effective Date”).
RECITALS
WHEREAS the parties desire for the Client to engage Consultant to perform the services described herein and for Consultant to provide such services on the terms and conditions described herein; and
WHEREAS, the parties desire to use Consultant’s independent skill and expertise pursuant to this Agreement as an independent contractor;
NOW THEREFORE, in consideration of the promises and mutual agreements contained herein, the parties hereto, intending to be legally bound, agree as follows:
B-1
B-2
B-3
B-4
B-5
B-6
In Witness Whereof, the parties have executed this Agreement effective as of the date first written above.
GlycoMimetics, Inc.
By: ____________________________________
Name: Xxxxxx Xxxxxxxxx
Title: President and Chief Executive Officer
Agreed to and Accepted:
________________________________________
Xxxx Xxxxxxx, Ph.D.
B-7
Exhibit C
Equity Awards (as of February 20, 2023)
Stock Options
Exercise Price | ISO/NSO | Total Number of Shares Originally Subject to Option | Vested | Unvested | Vesting Schedule for Unvested | Expiration Date | |
| | | | | | | |
1/10/2014 | $8.00 | ISO | 41,022 | 41,022 | 0 | n/a | 1/9/2024 |
1/10/2014 | $8.00 | NSO | 128,016 | 128,016 | 0 | n/a | 1/9/2024 |
1/8/2015 | $7.15 | ISO | 11,524 | 11,524 | 0 | n/a | 1/7/2025 |
1/8/2015 | $7.15 | NSO | 59,476 | 59,476 | 0 | n/a | 1/7/2025 |
1/7/2016 | $5.22 | NSO | 71,000 | 71,000 | 0 | n/a | 1/6/2026 |
1/4/2017 | $6.33 | NSO | 75,000 | 75,000 | 0 | n/a | 1/3/2027 |
1/10/2018 | $20.03 | NSO | 75,000 | 75,000 | 0 | n/a | 1/9/2028 |
1/17/2019 | $10.59 | NSO | 100,000 | 100,000 | 0 | n/a | 1/16/2029 |
1/22/2020 | $4.72 | NSO | 120,000 | 90,000 | 30,000 | Monthly through 1/22/24 | 1/21/1930 |
1/20/2021 | $3.81 | NSO | 69,000 | 34,500 | 34,500 | Monthly through 1/20/25 | 1/19/1931 |
1/21/2022 | $1.11 | NSO | 100,000 | 25,000 | 75,000 | Monthly through 1/20/26 | 1/20/1932 |
1/21/2022 | $1.11 | PSO | 25,000 | 0 | 25,000 | (1) | 1/20/1932 |
TOTAL: |
|
|
| 710,538 | 164,500 |
|
|
(1) 50% of the shares underlying this option will vest upon FDA approval of uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to Continued Service through the applicable vesting date.
C-1
Restricted Stock Units
Grant Date | Total Number of Shares Originally Subject to RSU | Vested and Previously Settled as Shares | Unvested and Outstanding | Vesting Schedule for Outstanding |
1/20/21 | 34,500 | 17,250 | 17,250 | 50% on 1/20/24 and 50% on 1/20/25 |
C-2